Bristol Myers Squibb Expands U.S. Manufacturing Presence to Advance Cancer Innovation

Investment in Indianapolis will bring groundbreaking treatments to cancer patients.

RayzeBio, a Bristol Myers Squibb company, opened a first-of-its-kind radiopharmaceutical manufacturing facility in Indianapolis, Indiana, bringing significant investment and high-skilled job opportunities to the region. The new site will serve as a hub for developing and delivering highly targeted, actinium-based radiopharmaceutical therapies (RPTs). These cutting-edge therapies deliver internal radiation directly to cancer cells and show potential for stronger treatment efficiency and better patient outcomes compared to traditional chemotherapy. The site will provide on-demand manufacturing and can deliver to the patient’s treatment center within just three days of release after production.

The RayzeBio facility is an important reminder of the vibrant ecosystem created through biopharmaceutical investment in American innovation, with support from policymakers in Indiana and Washington, D.C.  and ongoing collaboration with the local community. These investments must often occur years before a medicine reaches patients. “It is critically important that we have a policy environment that encourages companies to make those investments…and rewards innovation,” said Chris Boerner, Board Chair and CEO, Bristol Myers Squibb.

This investment is a part of a broader $40 Billion commitment from Bristol Myers Squibb over the next five years to expand its R&D, technology and manufacturing footprint across America and sustain continued U.S. biopharmaceutical leadership in drug discovery and development.

Bristol Myers Squibb is at the forefront of cancer innovation, driven by a strong commitment to bring novel treatments to patients and build the future of cancer care in America.